Aldeyra Therapeutics (ALDX) Operating Income (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Operating Income of -$3.5 million for Q1 2026, up 46.81% on a QoQ basis from -$6.7 million in Q4 2025, and up 65.98% year-over-year from -$2.1 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Operating Income (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Operating Income history runs 14 years deep, the most recent figure standing at -$3.5 million for Q1 2026.
- Quarterly Operating Income rose 65.98% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.4 million (up 53.58% YoY) and the FY2025 annual result came in at -$35.3 million, up 41.34% from the prior year.
- Operating Income was -$3.5 million for Q1 2026 at Aldeyra Therapeutics, up from -$6.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$3.5 million in Q1 2026 and bottomed at -$18.0 million in Q2 2024.
- A 5-year average of -$12.0 million and a median of -$10.4 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income plunged 171.87% — and 2026, when it surged 65.98%.
- Aldeyra Therapeutics' Operating Income stood at -$13.7 million in 2022, then soared by 55.48% to -$6.1 million in 2023, then tumbled by 171.87% to -$16.6 million in 2024, then jumped by 59.78% to -$6.7 million in 2025, then jumped by 46.81% to -$3.5 million in 2026.
- Business Quant data shows ALDX's Operating Income at -$3.5 million in Q1 2026, -$6.7 million in Q4 2025, and -$8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Aldeyra Therapeutics | 94.70 Mn | 94.70 Mn | - | -3.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.55 Mn |
| Dec 31, 2025 | -6.67 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Jun 30, 2025 | -10.17 Mn |
| Mar 31, 2025 | -10.43 Mn |
| Dec 31, 2024 | -16.58 Mn |
| Sep 30, 2024 | -16.14 Mn |
| Jun 30, 2024 | -18.01 Mn |
| Mar 31, 2024 | -9.39 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Sep 30, 2023 | -9.55 Mn |
| Jun 30, 2023 | -10.34 Mn |
| Mar 31, 2023 | -16.80 Mn |
| Dec 31, 2022 | -13.70 Mn |
| Sep 30, 2022 | -14.78 Mn |
| Jun 30, 2022 | -17.71 Mn |
| Mar 31, 2022 | -16.48 Mn |
| Dec 31, 2021 | -15.40 Mn |
| Sep 30, 2021 | -15.44 Mn |
| Jun 30, 2021 | -14.54 Mn |